Kamada (KMDA) Net Income towards Common Stockholders (2012 - 2026)
Kamada's (KMDA) quarterly Net Income towards Common Stockholders came in at $6.6 million in Q1 2026, down 28.2% YoY from $9.3 million in Q1 2025, and up 12.6% on a QoQ basis from $5.9 million in Q4 2025.
Kamada (KMDA) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Kamada (KMDA) has 15 years of Net Income towards Common Stockholders data on file, last reported at $6.6 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 28.2% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (up 38.82% YoY) and the FY2025 annual result came in at $26.7 million, up 119.04% from the prior year.
- Net Income towards Common Stockholders grew to $6.6 million in Q1 2026, from $5.9 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $9.3 million in Q1 2025 to a low of -$1809.0 in Q1 2023.
- A 5-year average of $3.3 million and a median of $3.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The widest YoY moves for Net Income towards Common Stockholders: up 537066.67% in 2023, down 100.1% in 2023.
- Tracing KMDA's Net Income towards Common Stockholders over 5 years: stood at $3.2 million in 2022, then surged by 53.68% to $5.0 million in 2023, then sank by 77.76% to $1.1 million in 2024, then surged by 432.07% to $5.9 million in 2025, then advanced by 12.6% to $6.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $6.6 million (Q1 2026), $5.9 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.60 Bn | 42.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.50 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.66 Bn | 22.86 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.22 Bn | 19.55 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.69 Bn | 15.30 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.07 Bn | 9.91 Bn | - | - |
| 10 | Kamada | 457.14 Mn | 427.66 Mn | 22.47 Mn | 9.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.26 Mn |
| Mar 31, 2026 | 6.65 Mn |
| Dec 31, 2025 | 5.91 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 6,328.00 |
| Mar 31, 2025 | 9.26 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | 4,552.00 |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 4.99 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | -1,809.00 |
| Dec 31, 2022 | 3.25 Mn |
| Sep 30, 2022 | 600.00 |
| Jun 30, 2022 | 3.95 Mn |
| Mar 31, 2022 | 1.83 Mn |
| Dec 31, 2021 | -4.82 Mn |
| Sep 30, 2021 | 868,000.00 |